This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer.
|Eligibility criteria|| |
Non-Small Cell Lung Cancer with an ALK mutation requiring treatment after curative surgery.
|Study details|| |
There is a screening period to assess eligibility. Patients are randomised to the current standard of care (chemotherapy) or alectinib, a targeted treatment. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW